Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Stress-strain phenotyping, reverse remodelling and therapeutic responsiveness in HFrEF: Predictive value of end-systolic wall stress and global longitudinal strain.

International journal of cardiology·2026

Same author

Late Embolization of a Patent Foramen Ovale Occluder Successfully Retrieved Percutaneously.

JACC. Case reports·2026

Same author

Predictive Value of Apelin-36 for No-Reflow Phenomenon in STEMI Patients.

Life (Basel, Switzerland)·2026

Same author

Predictive Value of Adiponectin for Long-Term MACEs in Non-Diabetic STEMI Patients.

Journal of clinical medicine·2025

Same author

GIANT ATRIAL SEPTAL ANEURYSM WITH THROMBI IN A PATIENT WITH ATRIAL SEPTAL DEFECT AND CEREBRAL ISCHEMIC EVENTS: A CASE REPORT.

Acta clinica Croatica·2025

Same author

Predictive Value of High-Sensitivity CRP Level on the No-Reflow Phenomenon in STEMI Patients.

Cardiology research and practice·2025

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Inflammation-Based C-Reactive Protein-to-Albumin Ratio for No-Reflow Prediction in STEMI.

Xhevdet Krasniqi^1,2, Altinë Spanca¹, Gresa Gojani¹

¹Department of Internal Medicine, Medical Faculty, University of Prishtina "Hasan Prishtina", 10000 Prishtina, Kosovo.

|June 26, 2026

Summary

The C-reactive protein/albumin ratio (CAR) can predict no-reflow in STEMI patients undergoing PCI. A CAR cut-off helps identify patients at higher risk for this complication.

Keywords:

CAR STEMI no-reflow phenomenon

Related Experiment Videos

Last Updated: Jun 27, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Area of Science:

Cardiology
Biochemistry
Clinical Diagnostics

Background:

The C-reactive protein/albumin ratio (CAR) is gaining recognition as a predictive marker for acute myocardial infarction (AMI).
Inflammation plays a crucial role in the pathophysiology of AMI and its complications.

Purpose of the Study:

To investigate the predictive capability of the CAR for the development of the no-reflow phenomenon in ST-elevation myocardial infarction (STEMI) patients.
To assess the diagnostic accuracy of CAR compared to other biomarkers for no-reflow.

Main Methods:

A cohort of 201 STEMI patients undergoing percutaneous coronary intervention (PCI) was analyzed.
Admission laboratory data, including C-reactive protein (CRP) and albumin, were collected to calculate CAR (CRP/albumin ×100).
Receiver operating characteristic (ROC) curve analysis was performed to determine the predictive value of CAR and other markers for no-reflow.

Main Results:

The CAR demonstrated a high area under the curve (AUC) of 0.9 (95% CI, 0.84-0.95) for predicting no-reflow.
A CAR cut-off value of 48.4 was identified, with higher levels significantly associated with no-reflow.
CAR was found to be a significant predictor of TIMI flow grade ≤ 2, alongside other markers like CRP and albumin.

Conclusions:

The CAR is a reliable and accessible biomarker for identifying the no-reflow phenomenon in STEMI patients post-PCI.
The proposed CAR cut-off can aid in stratifying patients at increased risk of no-reflow, potentially guiding clinical management.
CAR offers a valuable tool for risk stratification in AMI patients, complementing existing diagnostic parameters.